The in vivo specificity of BCY18469 towards EphA2 was proven by both PET imaging in an EphA2-negative cell line (MCF-7) and blocking with an excess on non-radiolabeled BCY18469, with both experiments showing no significant uptake and no tumor-to-background contrast (Figure 3). Here, EPHA2 is linked to neoplasm.